title: Measurement of MBF by PET is ready for prime time as an integral part of clinical reports in diagnosis and risk assessment of patients with known or suspected CAD : For prime time not yet: Need impact and certainty.
authors.affiliation: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, 650 Charles E Young Drive South, Los Angeles, CA, 90095, USA. hschelbert@mednet.ucla.edu.
authors.forename: Heinrich
authors.initials: H
authors.lastname: Schelbert
mesh_terms: D002309:Cardiology / Q000379:methods; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging*; D003326:Coronary Circulation; D019788:Fluorodeoxyglucose F18; D006439:Hemodynamics; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D055414:Myocardial Perfusion Imaging; D049268:Positron-Emission Tomography; D015203:Reproducibility of Results; D018570:Risk Assessment; D012984:Software; D014665:Vasodilator Agents
chemical_list: D014665:Vasodilator Agents; D019788:Fluorodeoxyglucose F18